Categories AlphaGraphs, Earnings, Other Industries

Eylea lifts Regeneron Q2 earnings

Regeneron Pharmaceuticals Thursday reported better-than-expected second quarter earnings of $5.45 per share on a revenue of $1.6 billion. Revenue for the quarter rose 9% year-over-year driven by strong US sales growth of Eylea and Dupixent drugs. On a GAAP basis, net income jumped 44% to $4.82 per share.

In the US, Eylea sales grew 8% to $992 million, while Dupixent saw its sale grow more than six times to $181 million.

Regeneron Pharmaceuticals second quarter 2018 earnings

“We are particularly pleased by US launch progress with Dupixent for adults with moderate-to-severe atopic dermatitis, driven by a positive experience in the marketplace by patients and physicians in this serious disease,” said CEO Leonard Schleifer in a statement.

In the second half of the year, the company anticipates two significant US regulatory approvals –cemiplimab for cell cancer and Dupixent for uncontrolled asthma.

In the second half of the year, the company anticipates two significant US regulatory approvals –cemiplimab for cell cancer and Dupixent for uncontrolled asthma.

The pharma-giant lowered its CapEx guidance for the full-year to $410-450 million from the prior guidance of $420-480 million. Outlook for effective tax rate was lowered to 13-16% from the earlier projected range of 15-18%.

Regeneron Q2 earnings conference call transcript

Regeneron shares rose 1% during early trading.

Most Popular

Should investors worry about Micron’s (MU) weak Q4 results and guidance?

The semiconductor industry is a rapidly growing business segment that currently thrives on the digital transformation wave. The demand for memory chips and other semiconductor products increased over the years,

What has Bed Bath & Beyond (BBBY) outlined for this fiscal year?

Shares of Bed Bath & Beyond (NASDAQ: BBBY) were up on Friday, a day after the company delivered disappointing results for the second quarter of 2022. The company reported a

NKE Earnings: Highlights of Nike’s Q1 2023 results

Nike, Inc. (NYSE: NKE) has reported a decrease in net profit for the first quarter of 2023, despite a modest increase in revenues. The company's stock suffered a big loss

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top